东宝生物(300239) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥241,778,598.22, a decrease of 7.48% compared to ¥261,319,537.08 in the same period last year[5] - Net profit attributable to shareholders was ¥25,961,526.88, down 16.62% from ¥31,137,429.27 year-on-year[5] - Basic earnings per share decreased to ¥0.0437, down 16.76% from ¥0.0525 in the same period last year[5] - Net profit for Q1 2024 was CNY 28,081,767.64, a decline of 19.2% from CNY 34,687,227.19 in Q1 2023[22] - The net profit attributable to shareholders of the parent company was CNY 25,961,526.88, down 16.9% from CNY 31,137,429.27 in the previous year[23] Cash Flow - The net cash flow from operating activities improved to -¥9,408,089.36, a 57.24% increase compared to -¥22,004,098.25 in the previous year[5] - The net cash flow from operating activities for Q1 2024 was -9,408,089.36 CNY, an improvement from -22,004,098.25 CNY in Q1 2023[26] - The company’s cash inflow from operating activities totaled 136,276,694.96 CNY, compared to 124,794,028.45 CNY in Q1 2023, reflecting a year-over-year increase[26] - The total cash outflow from operating activities was 145,684,784.32 CNY, slightly lower than 146,798,126.70 CNY in the same quarter last year[26] - The company reported a financial expense of CNY -1,700,412.18, compared to CNY 198,304.19 in the previous year, indicating improved financial management[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,755,359,790.94, reflecting a slight increase of 0.49% from ¥2,742,011,238.13 at the end of the previous year[5] - Total liabilities as of Q1 2024 were CNY 833,079,077.16, a slight decrease from CNY 848,818,198.38 in the previous year[22] - The total number of common shareholders at the end of the reporting period is 25,755[14] - The total equity attributable to shareholders increased by 1.57% to ¥1,684,029,096.94 from ¥1,658,061,663.67 at the end of the previous year[5] - Total equity increased to CNY 1,922,280,713.78 from CNY 1,893,193,039.75 year-over-year[22] Research and Development - Research and development expenses decreased by 32.00% to ¥4,046,567.55 from ¥5,950,698.74 in the previous year[11] - Research and development expenses for Q1 2024 were CNY 4,046,567.55, down from CNY 5,950,698.74 in Q1 2023[22] Income and Expenses - The company reported a significant increase in other income, which rose by 122.81% to ¥2,868,307.89 compared to ¥1,287,359.67 in the previous year[11] - The company experienced a 681.72% increase in other operating expenses, totaling ¥875,742.61 compared to ¥112,027.07 in the previous year[11] - Total operating costs for Q1 2024 were CNY 209,838,876.06, down 5.0% from CNY 220,984,145.75 in the same period last year[22] Cash and Cash Equivalents - The company's cash and cash equivalents increased to ¥759,897,550.09 from ¥748,691,388.11[17] - Cash and cash equivalents at the end of Q1 2024 stood at 715,787,550.09 CNY, up from 257,633,996.41 CNY at the end of Q1 2023[27] - The net increase in cash and cash equivalents for Q1 2024 was 2,336,158.08 CNY, contrasting with a decrease of 80,823,303.64 CNY in the previous year[26] Shareholder Information - The largest shareholder, Qingdao Guoen Technology Co., Ltd., holds 21.18% of shares, totaling 125,711,022 shares, with 88,000,000 shares pledged[14] - The total number of preferred shareholders is zero, indicating no preferred shares outstanding[16] - The company has no significant changes in the top ten shareholders participating in margin trading[15] Investment Activities - The net cash flow from investing activities was ¥9,150,743.28, an increase of 185.48% from ¥10,705,182.69 in the previous year[13] - Total cash inflow from investment activities was 33,220,361.53 CNY, significantly higher than 15,000.00 CNY in the same period last year[26] Audit Information - The company did not undergo an audit for the Q1 2024 report[28]